Scienza e Tecnologia
China's gene-editing landscape advances as CVC's second CRISPR/Cas9 patent granted
ERS, co-founded by Dr. Emmanuelle Charpentier , 2020 Nobel Prize winner for gene-editing, provides access to the foundational CRISPR/Cas9 intellectual property. With this patent in China , the fundamental value of gene-editing technology is officially validated within the scientific community. The patent covers methods and compositions for RNA-Directed target DNA modification and for RNA-Directed modulation of transcription.
ERS has recently established a formal presence in China with new hire, , formerly of Illumina. Speaking to the new patent, Jojo had the following to say:
CVC refers to University of alifornia, University of ienna, and Emmanuelle harpentier. It describes the owners of what are commonly known as the UC Berkeley CRISPR patents. CVC and Dr. Charpentier hold patents to this game-changing gene-editing technology in over 80 countries worldwide.
ERS Genomics is a biotechnology company based in
Dublin, Ireland . The company was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property held by Dr.
Emmanuelle Charpentier . Non-exclusive licenses are available for research and sale of products and services across multiple fields including: research tools, kits, reagents; discovery of novel targets for therapeutic intervention; cell lines for discovery and screening of novel drug candidates; GMP production of healthcare products; companion animal and livestock health; production of industrial materials such as enzymes, biofuels and chemicals; and synthetic biology. For additional information please visit www.ersgenomics.com
Photo: https://mma.prnewswire.com/media/1682039/Arciero_ERS.jpg
Photo: https://mma.prnewswire.com/media/1682040/Jojo_ERS.jpg
Logo: https://mma.prnewswire.com/media/1682041/ERS_Logo.jpg